Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma

Background: Regorafenib is a second-line therapy drug used for advanced hepatocellular carcinoma (HCC). Unfortunately, the survival benefit of the patients receiving this treatment is modest, which may be attributed to drug resistance. In the present study, sphingosine kinase 2 (SphK2) was targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Weiwei, Zhang, Shan, Ma, Ding, Yan, Dongliang, Zhang, Guang, Cao, Yin, Wang, Zhongxia, Wu, Junhua, Jiang, Chunping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327090/
https://www.ncbi.nlm.nih.gov/pubmed/32670862
http://dx.doi.org/10.3389/fonc.2020.00694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327090/
https://www.ncbi.nlm.nih.gov/pubmed/32670862
http://dx.doi.org/10.3389/fonc.2020.00694

Ejemplares similares